Anti-SARS-CoV-2 Antibody Status at the Time of Hospital Admission and the Prognosis of Patients with COVID-19: A Prospective Observational Study
Open Access
- 11 December 2022
- journal article
- research article
- Published by MDPI AG in Infectious Disease Reports
- Vol. 14 (6) , 1004-1016
Abstract
The association between COVID-19 severity and antibody response has not been clearly determined. We aimed to assess the effects of antibody response to SARS-CoV-2 S protein at the time of hospital admission on in-hospital and longitudinal survival. Methods: A prospective observational study in naive hospitalised COVID-19 patients. The presence of anti-S SARS-CoV-2 IgM and IgG was evaluated using a lateral flow assay at the time of admission. The patients were followed up for 8–30 months to assess survival. We recruited 554 patients (330 men and 224 women). Overall, 63.0% of the patients had positive IgG or IgM anti-S SARS-CoV-2 antibodies at the time of hospital admission. In the univariate analysis, the patients with negative anti-S SARS-CoV-2 IgM and IgG antibodies were referred to the hospital sooner, had lower CRP and D-dimer concentrations, and were hospitalised longer. They were also more likely to be admitted to an intensive care unit and more often received baricitinib treatment. During their hospital stay, 8.5% of the antibody-positive and 22.3% of the antibody-negative patients died (p = 0.0001). The median duration of the follow-up was 21 months. During the follow-up after hospital discharge, 3.6% of antibody-positive and 9.1% of antibody-negative patients died (p = 0.027). In the multivariate analysis, the negative anti-S SARS-CoV-2 antibodies were associated with a higher risk of in-hospital death (OR 3.800; 95% CI 1.844–7.829; p = 0.0001) and with a higher risk of death during follow-up (OR 2.863; 95% CI 1.110–7.386; p = 0.030). These associations were independent of age, the time from symptom onset to hospital admission, CRP, D-Dimer, the number of comorbidities, disease severity at the time of hospital admission, and baricitinib therapy. Our study concludes that negative anti-S SARS-CoV-2 IgM and IgG at the time of admission are associated with higher in-hospital mortality and cause a higher risk of all-cause death during follow-up after discharge.Keywords
This publication has 32 references indexed in Scilit:
- Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 MortalityCell, 2020
- Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort studyRheumatology, 2020
- SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumoniaBiomedicine & Pharmacotherapy, 2020
- Distinct Early Serological Signatures Track with SARS-CoV-2 SurvivalImmunity, 2020
- Predictors of COVID‐19 severity: A literature reviewReviews in Medical Virology, 2020
- Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene BiotechJournal of Clinical Microbiology, 2020
- Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19Critical Care, 2020
- Serum IgM against SARS-CoV-2 correlates with in-hospital mortality in severe/critical patients with COVID-19 in Wuhan, ChinaAging, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Beyond binding: antibody effector functions in infectious diseasesNature Reviews Immunology, 2017